A.K. So we consecutively evaluated the patients that were referred to us for a standard routine staging for computed tomography. We used our dual-energy exam for them and then we tried to acquire them for the MRI.
D.A.B. Okay.
A.K. We took great care that there is no time between MRI and CT scan so that no anti myeloma treatment is delivered.
D.A.B.
Okay. And you choose patients with multiple myeloma just to be specific about the diagnosis or you had a lot of those patients coming to CT anyway? Is that the reason?
A.K. So they got referred to us from the internal medicine department with the diagnosis or with the suspected diagnosis of multiple myeloma. There were 28 follow-ups and I think 6 primary diagnosis.
Okay. So the idea is to look at the essentially the performance or accuracy of dual-energy CT and your standard of reference was an MRI?
A.K. That was MRI right.
D.A.B. Okay so everybody had both exams.
A.K. Yes.
D.A.B.
What was the time difference between the two exams was it pretty close?
A.K. In most patients we tried to do it on the same day.
D.A.B. Oh, okay.
A.K. So most patients we managed to do this, but some patients they were not in-patients but they came back and in some cases I think the biggest data was around 60 days. D.A.B. So in order to use dual-energy CT to detect bone marrow infiltration by myeloma what sort of techniques did you use with dual-energy CT? How did you do it?
A.K. In order to -the contrast of computed tomography images result from differences in photon attenuation. Mainly based on the photoelectric effect. I think the attenuation of a given tissue depends on one hand on the material of which it consists, and on the other hand of the photon energies that you use to examine it with. So if you have a given photo energy for example created by a tube of 120 kV and use and you examine different materials than you get different attenuation values. But if you have a constant specific material and use different photon energies then you also receive a set of different attenuation values. And this is characteristic for different materials.
D.A.B.
Okay so what energies did you use for the dual-energy CT scan or what energy levels did you use?
A.K. We choose the 90 kV for the low kV tube and 150 kV with a tin filter for the high kV tube.
D.A.B. Okay a tin filter, what's the purpose of that tin filter?
A.K. The tin filter hardens the high kV spectrum so it filters the low energy parts of the spectrum and that creates a better spectral separation between the low kV tube and the high kV tube.
D.A.B.
So you have a more pure high energy versus the low energy because there's still overlap between this?
A.K. Yes, but it minimizes the overlap.
Okay. So you have two energies and those photons are gonna through different materials. They're gonna go through fat in normal marrow primarily fat and then if you have tumor you're looking for multiple myeloma those photons are going to be going through tumor. And so what are you expecting if there's two energies and perhaps you're going to take the high energy versus the low energy, the photons are going through tumor tissue, you're gonna have different Hounsfield unit measurements right?
A.K. Right.
Okay and how different are those energies at let's say the 90 and the 150? Are the Hounsfield units similar or do they start to get quite different for those?
A.K. So what we didn't measure in the 90 kV and the 150 kV data sets, but what we received were Hounsfield measurements that were already from the virtual noncalcium data set.
Okay. So the Hounsfield units let's say one type of tissue if it were all fat the 90 kV is a little higher Hounsfield units than the 150 kV. But I believe that at the 150 high energy there's a larger difference for the tumor tissue right, the myeloma?
Okay so there's a broader differentiation between the 90 kV which represents its signature and a dual-energy scan.
Okay. So also the unique aspect of this paper and new innovation is three material separation right? Could you tell us a little about that because you had to separate calcium, fat which is benign tissue, and then tumor tissue which is higher density.
A.K. Yes, right. So there is this three material decomposition algorithm that has been used before and it differentiates as you said calcium, fat and red marrow or soft tissue or tumorous tissue which are assigned specific attenuation numbers and then those materials can be quantified and consequently virtually removed.
Okay, so as you're going into it you realize then already I suppose the fat Hounsfield units probably relatively specific for fat?
Okay but what about the tumor? The tumor we know soft tissues are soft tissues, some overlap with other tissues perhaps you have to understand going in maybe other types of red marrow might overlap?
A.K. Yes this was the tumor Hounsfield units were non-specific so it was not obviously a tumor, but it was elevated when you compare it to the normal background of healthy, fatty bone marrow that you would expect in those populations.
So we have this understanding that fat, you're gonna get a signal that's pretty characteristic and then you're gonna get another signal and you still have to make an interpretation of whether that signal you're getting is actually tumor or maybe there's different patterns that might be -you want to make sure it's not hemopoietic marrow or edema perhaps or something like that.
A.K. Right. Yes, yes, yes.
Okay, good. So those are the methods, tell us about the main results of the study. How well did it work?
A.K. It worked actually quite well. We did a two-step analysis. The first part of the analysis was the visual analysis so we just looked at the patient based results, whether we could classify a patient as having bone marrow infiltration or not.
D.A.B. Okay.
A.K. And compared to standard CT in five cases we were able to detect bone marrow infiltration that was not visible on standard CT.
A.K. This was one of the most important pieces.
D.A.B.
So it just helped you with the basic CT and that alone might be a win I think right?
Okay. So you did visual analysis, you found some patients you mentioned five patients that worked better than conventional CT and that was five of out of about how many patients?
A.K. Five out of I think 23 patients that had infiltration.
Yeah so that's a good percentage. That may be helpful in those patients. So in addition to looking at a per patient analysis you also measured a lot of regions of interest.
D.A.B. So what was the purpose of that?
A.K. We wanted to show that not only in visual analysis and on a per patient base, but also on a per lesion base and with a quantitative approach it's possible to differentiate healthy marrow from infiltrated marrow. So we measured, guided by MRI, we measured the attenuation numbers of lesions and of controlled regions.
D.A.B.
Okay so MRI is your reference and say this area is really normal by MRI what are the Hounsfield unit measurements are what are the signals that we're getting and how do they compare? That also gives you a lot more data potentially some overlap but you get a lot more data points you get a little bit better statistics that way I suppose.
Yep so then you have was it almost hundreds of data points with regional interest of… A.K. We had 245 points of interest.
Okay. Lots of areas normal versus abnormal and how did the quantitative results turn out compared to the visual results. What were the quantitative results?
A.K. The numbers were actually quite similar. So when it comes to diagnostic performance we had sensitivities and specificities a little bit above 90% so it was comparable.
Okay so that sensitivity and specificity I noticed they were pretty consistent. Sometimes some of our tests are very highly sensitive, but have a low specificity or vice versa. It's kind of helpful that we're not over calling or under calling in that sense. So that was pretty encouraging and almost kind of reassuring that the quantitative numbers corresponded to the visual assessment of the per patient analysis.
So that was really quite nice. Okay. And any other results that came to mind? How did the images look? How did you like the image quality as a radiologist?
A.K. The images -so you don't only get the 90 kV image and the 150 kV image but a third data set of 120 kV "like" images created and those look, in my opinion, comparable to what you're used to.
Okay. And to detect the tumor, the myeloma let's say in the infiltrated marrow, you were using a virtual non-calcium image.
D.A.B. I think we're mostly familiar with virtual non-contrast iodine image, so how does that differ the virtual non-calcium? How do you do that or what is that?
A.K. So basically it all comes back to the three material decomposition algorithm that is used to quantify in our case calcium and if you can quantify it and you can also virtually subtract it from the image information.
D.A.B.
Okay so if I understand correctly you create the calcium map and you subtract it out of the other material leaving let's say the fat and the water image primarily?
A.K. The fat and the soft tissue or red marrow images.
Okay. And then that was a color overlay then where you are looking at that and I looked at some of the images, the viewers can look at the images in the manuscript and you color coded the images. It seemed like there was a lot of variation in the color maps. What's your assessment as a radiologist because it seemed like the variation would be hard to interpret. Do you have to look at a lot of those?
A.K. Yes I think in my opinion it's not -in some cases it is self-explanatory, but sometimes you really have to look at the dual-energy overlay at the CT image and really think whether it is an artifact or whether this can be real.
Okay so there's still some interpretation involved but it's potentially an interpretative tool to help you with that diagnosis of marrow abnormalities.
A.K. Exactly. A.B . Okay, got it. Okay so you've done the study, you have sensitivity and specificity and a smaller study right now, a preliminary study of a little over 30 patients, what would you say are the potential limitations with the technique? Where -you had a couple false positives and a false negative, what happens in those cases?
D.
A.K. Yes I think the false negatives those were patients that had very small lesions on the MRI imaging around 6 or 7 mm solitary lesions, and the first problem is to actually see them on the dual-energy CT images and the second step is to if you see them then you really have to think whether this is real, whether this can be a solitary tiny lesion or whether this is just an artifact. And I think at this first stage we were not confident enough to call it a solitary 5 mm lesion and just didn't really count this patient as infiltrated.
D.A.B. Okay, got it.
A.K. So this is how I would explain the false negatives. The false positives on the other hand I think they are mainly because the elevation in attenuation numbers is not specific to multiple myeloma. That can happen due to degenerative cases (inaudible). So it's not specific and I think this is how you can explain the false positives. Some patients showed artifacts and one patient even the artifacts looked like focal infiltrations so both me and the other reader we both classified the same patient as positively infiltrated and he was not.
D.A.B.
Okay. One or two other questions then just on your results and how this may work, you looked at the spine and the pelvis, does the technique work better in one area or another or is it quite similar in either area, any difference?
A.K. Yes. It's important that there is lots of background of healthy fatty marrow and when you go from cranial to caudal in the body you get more fatty bone marrow. So it's physiological that in the lumbar spine there is more fatty marrow than in the thoracic spine and in the pelvis there is even more so it works best if there is lots of fatty background.
Got it. So if a patient's anemic perhaps and they have a lot of hemopoietic marrow may be a challenge to do that?
Got it. Good. Now the other thing that comes to mind, MRI for a diagnosis of myeloma is pretty straightforward. There's a lot of contrast-to-noise ratio, the abnormal lesions are really bright and inversion recovery sequence. So that's clear and that probably works pretty well on CT as well. Just reading your technology and looking at the images, but sometimes myeloma has a more difficult pattern maybe a salt and pepper pattern?
D.A.B. How did you deal with that?
A.K. This was one important limitation of our paper that we had only patients that were normal and patients with focal lesions and we completely missed patients with diffuse infiltration. For example this is really an important pattern that has to also be diagnosed.
D.A.B.
Okay. And would that pattern be amenable to further technological refinement of the technique or is that going to be a limitation of this method in general?
A.K. We kept on examining those patients so now we have patients with this infiltration of combined diffuse and focal infiltration and it also works. It's possible to detect it.
D.A.B. Good so it's a learning curve and maybe getting the technology improvement as well is that right?
A.K. I think it's a learning curve for the examiner. So really you have to look at some of those pictures and really have to in some cases have the MRI to learn what it looks like. D.A.B. I see. So having the MRI to guide you and interpret the images because the images were the first time, essentially almost the first time done and so it's hard to know what is normal and abnormal the first time you do the study. Got it. Okay. So just to conclude then, what would be the next steps for the technique? Are you continuing to use it? Are more patients examined? Where is it going?
A.K. Yes we are continuing to use it. We want to examine different patterns of myelomatosis infiltration. So for MRI the patterns are established and for CT it's only possible to detect lytic lesions so we want to try to establish maybe a different CT patterns comparable to MRI patterns as well for dual-energy.
D.A.B. Okay.
A.K. And I think an important point to look into is how treatment related changes look in dual-energy computed tomography. So if we get one patient and primary diagnosis and then look at therapeutic monitoring with dual-energy this will be certainly important for the future. D.A.B. Good. And with CT we always have that concern about radiation exposure. With the dual-energy technique how's the radiation exposure going to compare to a standard CT acquisition?
A.K. So there are different papers out there actually. Some of them tell us that in some cases the radiation exposure is higher; some tell us that it's lower. For example we did pulmonary embolism with dual-energy CT and we were able to lower the radiation exposure. So this is an important point to look into and we'll certainly do it. But comparing to our previous generation scanners, using dual-energy CT we're still below what we used to have at the for example 64 (inaudible) scanner.
D.A.B.
Okay so that's encouraging. So your experience now in radiation is under control.
Maybe we'll get lower than earlier generations. Good. Good to know. Okay, so any other final thoughts on the success of dual-energy? You did a study on trauma; you did a study on tumors, any other studies with bone marrow and bone with dual-energy that you're thinking about?
A.K. We are continuing to do the multiple myeloma patients to look into the patterns and the therapy and use changes and we'll certainly keep looking.
Aleksander, thank you very much.
A.K. Thank you very much.
D.A.B. Very nice paper.
A.K. Thank you.
